Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, PhD, Shirong Li, Huihui Ma, MD PhD, Jun Yang, MS, Gabriel M. Pagnotti, PhD, Stephen J. Weiss, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142528

Published: 2020

Journal Articles

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

David W Harle, BBiomedSc, Rodney J Macedo Gonzales, MD PhD, Felix D Rozenberg, BSc, Alexandra Matschiner, Rajat Bansal, MD, Stephen M Lagana, MD, Huihui Ma, MD PhD, Elisha Pinker, Kirubel S Belay, BSc, Ximi K Wang, BSc, Tiffany Thomas, PhD, Markus Y Mapara, MD PhD, Anne-Catrin Uhlemann, MD, Yi Zhang, MD PhD, Ran Reshef, MDMSc

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-143105

Published: 2020

Journal Articles

Interferon Gamma (IFNγ)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD)

Caisheng Lu, MD PhD, Huihui Ma, MD, PhD, Liangsong Song, MD, PhD, Shirong Li, PhD, Suzanne Lentzsch, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 2147.

https://doi.org/10.1182/blood.V128.22.2147.2147

Published: 2016

Journal Articles

Inhibition of Graft-Versus-Host-Disease (GVHD) by Treatment with the Cyclopentenone Prostaglandin 15d-PGJ2 Involves Modulation of the NF-κB Signaling Pathway.

Huihui Ma, MD, PhD, Judith Ziegler, BS, CMT, Suzanne Lentzsch, MD, PhD, Markus Mapara, MD, PhD

Blood (2007) 110 (11): 3238.

https://doi.org/10.1182/blood.V110.11.3238.3238

Published: 2007

Journal Articles

Cucurbitacin I (JSI-124) Has Potent Anti-Myeloma Effects Independent of Its Inhibition of JAK2-Induced STAT3 Activation.

Huihui Ma, MD, PhD, Judith Ziegler, BS, CMT, Ren-Tien Feng, PhD, Suzanne Lentzsch, MD, PhD, Markus Mapara, MD, PhD

Blood (2007) 110 (11): 2521.

https://doi.org/10.1182/blood.V110.11.2521.2521

Published: 2007

NARROW

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

Interferon Gamma (IFNγ)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD)

Inhibition of Graft-Versus-Host-Disease (GVHD) by Treatment with the Cyclopentenone Prostaglandin 15d-PGJ2 Involves Modulation of the NF-κB Signaling Pathway.

Cucurbitacin I (JSI-124) Has Potent Anti-Myeloma Effects Independent of Its Inhibition of JAK2-Induced STAT3 Activation.

Email alerts

ASH Publications

American Society of Hematology

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

Interferon Gamma (IFNγ)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD)

Inhibition of Graft-Versus-Host-Disease (GVHD) by Treatment with the Cyclopentenone Prostaglandin 15d-PGJ2 Involves Modulation of the NF-κB Signaling Pathway.

Cucurbitacin I (JSI-124) Has Potent Anti-Myeloma Effects Independent of Its Inhibition of JAK2-Induced STAT3 Activation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only